However, TKI resistance is problematic in TKI-treated patients, and the molecular mechanisms are probably due to the T315I mutation, K89M mutation and ETV6-ABL1-independent TKI resistance in a single patient.19 For AML patients, 6 of 12 were given TKIs, but the longest survival time was seven months. Here, ABL1 is linked to acute myeloid leukemia.